Author(s): Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, , Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P,
Abstract Share this page
Abstract In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42\%), 18 605 autologous (58\%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32\%; 94\% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57\%; 12\% allogeneic); solid tumours; 1573 (5\%; 5\% allogeneic); and non-malignant disorders; 1830 (6\%; 92\% allogeneic). There were more unrelated donors than HLA identical sibling donors (54\% versus 39\%); proportion of peripheral blood as stem cell source was 99\% for autologous and 73\% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6\% of total). In the past 10 years, the overall number of transplants has increased by 53\%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32\% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.
This article was published in Bone Marrow Transplant
and referenced in Journal of Blood Disorders & Transfusion